|Treatment Intensification Rates, Baseline Risk Factor Levels, Declines and Adjusted Mean Differences During Follow-up - Processed vs. Not Processed Patients, Intervention Centers Only, by Priority Level|
|Priority||Percent Processed†||Intensified within 3 mos (%)||Baseline Mean Risk Factor Level‡||Unadjusted Decline¶||Intensified within 3 mos (%)||Baseline Mean Risk Factor Level‡||Unadjusted Decline¶||Adjusted Difference (Processed – not Processed) During Follow-up (95% CI)€|
|1: SBP ≥ 140 mmHg||45||40.5||153.4||13.1||28.8||153.0||14.1||1.01|
|2: LDL-c ≥ 130 mg/dL||46||36.3||152.8||25.9||21.0||153.4||24.0||-0.6|
|3: A1c ≥ 9%||47||32.6||10.3||1.0||26.7||10.2||1.0||-0.03|
|5: LDL-c 100-129 mg/dL||30||29.2||111.2||10.4||16.8||111.4||10.0||0.63|
|6. A1c 7-8.9%||28||28.9||7.6||-0.1||25.3||7.5||-0.1||-0.03|
† Processed: Record review and outreach initiated by staff in response to identification of eligibility for treatment intensification.
‡ Based on the last value recorded before follow-up begins; i.e., the value that qualified patient for treatment intensification.
¶ Based on the first value recorded after 3 months follow-up; if no values recorded between 3 and 12 months follow-up, the latest value recorded during first 3 months follow-up was used.
€ From repeated measures models using all available values during follow-up,with adjustment for age, gender, race-ethnicity, baseline risk factor value, number of medications for the risk factor at baseline, and days of follow-up at time of each measurement. Negative value indicates that the adjusted values were lower in the processed group during follow-up.
£ Only patients with diabetes mellitus and/or chronic kidney disease were eligible for the target of SBP <130 mmHg.
Selby et al.
Selby et al. BMC Health Services Research 2012 12:183 doi:10.1186/1472-6963-12-183